Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million
GOTHENBURG, Sweden, May 7, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the […]
Regulatory
Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States
GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced approval
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million
GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that
Patent detecting how patients respond to folate-based cancer treatment approved in the USA
GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announces the approval from
Isofol’s board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company
GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that the board
Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin
GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a
Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States
GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a
Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin
GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from
Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin
GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from
First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer
GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first